Novartis Korea announced on the 17th that Beovu, an Age-related macular degeneration treatment, has added diabetic macular edema (DME). Beovu is a treatment that inhibits neonatal vascular expression and retinal effusion leakage in combination with VEGF-A. The Beovu dose for DME treatment is administered once every 6 weeks, 6 mg (0.05 mL) for the first 5 times, and once every 12 weeks thereafter. Patients with disease activity can be administered once every eight weeks. The administration interval is determined based on disease activity evaluated on vision and/or anatomical criteria. This permission was based on the results of 2 phase 3 clinical trials, KESTREL and KITE, which directly compared the efficacy and safety